Homology responds to reproducibility concerns

Homology is pushing back against a USC preprint study calling the reproducibility of the company’s cut-free gene editing platform into question. The study, which the company says stands in contrast to years of data supporting the technology, prompted investors to drive down the stock 20% on Thursday.

The new study, published Sunday on

Read the full 527 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE